|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 18.00 USD | -2.60% |
|
-3.51% | +44.58% |
| 10-21 | JPMorgan Adjusts Viatris Price Target to $20 From $18 | MT |
| 10-16 | Viatris Gets FDA Approval for Ryzumvi in the Treatment of Presbyopia | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VIATRIS INC. | Other Pharmaceuticals | -2.60% | -3.51% | +44.58% | +73.91% | +30.43% | 20.67B |  | | |
- Stock Market
- Stocks
- VTRS Stock
- Charts Viatris Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
